RT Journal Article
T1 Serum metabolites in non-alcoholic fatty-liver disease development or reversion  a targeted metabolomic approach within the PREDIMED trial.
A1 Papandreou, Christopher
A1 Bullò, Mònica
A1 Tinahones, Francisco José
A1 Martínez-González, Miguel Ángel
A1 Corella, Dolores
A1 Fragkiadakis, Georgios A
A1 López-Miranda, José
A1 Estruch, Ramon
A1 Fitó, Montserrat
A1 Salas-Salvadó, Jordi
K1 Fatty acid metabolism
K1 Hepatic lipotoxicity
K1 Metabolomics
K1 Non-alcoholic fatty liver disease
AB Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characterized as NAFLD cases during the follow-up (n = 15); Group 2, characterized as NAFLD during the follow-up (n = 15); Group 3, characterized as NAFLD-reversion during the follow-up (n = 15). At baseline, significantly lower storage and transport lipids (triacylglycerols and cholesteryl esters), several monoetherglycerophosphocholines, acylglycerophosphocholines, ceramides and ceramide to sphingomyelin ratio (P  The rearrangement of lipid biosynthesis and serum transport may indicate predisposition to NAFLD development. Despite an expected reduction of hepatic lipotoxicity and improved hepatic function in the participants of the study characterized as NAFLD-reversing, the side effects of NAFLD in serum metabolic profiles remained present. The trial is registered at ISRCTN35739639. Registration date: 5th October 2005.
SN 1743-7075
YR 2017
FD 2017-09-02
LK https://hdl.handle.net/10668/25790
UL https://hdl.handle.net/10668/25790
LA en
DS RISalud
RD Apr 6, 2025